AUTL AUTOLUS THERAPEUTICS LTD revenue, earnings and financials
For the quarter ended June 30, 2026, AUTOLUS THERAPEUTICS LTD reported revenue of $45.7M (up 118.4% from a year earlier), net income of −$39.1M and diluted EPS of −$0.15; over the last four quarters revenue was $117M and net income −$280M; for the fiscal year ended December 2025 revenue was $75.4M, up 644.9% on the year before.
AUTL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $75.4M, gross profit n/a, operating income −$271M, net income −$288M (margin -381.4%), EPS −$1.08
- Fiscal year ended Dec 2024: revenue $10.1M, gross profit n/a, operating income −$241M, net income −$221M (margin -2180.5%), EPS −$0.86
- Fiscal year ended Dec 2023: revenue $1.70M, gross profit n/a, operating income −$180M, net income −$208M (margin -12272.3%), EPS −$1.20
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$143M, net income −$149M (margin n/a), EPS −$1.57
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$141M, net income −$142M (margin n/a), EPS −$1.97
AUTL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $45.7M (up 118.4% year over year), net income −$39.1M, EPS −$0.15
- Quarter ended Mar 31, 2026: revenue $26.2M (up 191.9% year over year), net income −$71.6M, EPS −$0.27
- Quarter ended Dec 31, 2025 (from the annual report): revenue $24.3M (up 83655.2% year over year), net income −$90.3M, EPS −$0.34
- Quarter ended Sep 30, 2025: revenue $21.2M, net income −$79.1M, EPS −$0.30
- Quarter ended Jun 30, 2025: revenue $20.9M, net income −$47.9M, EPS −$0.18
- Quarter ended Mar 31, 2025: revenue $8.98M (down 11.0% year over year), net income −$70.2M, EPS −$0.26
- Quarter ended Dec 31, 2024 (from the annual report): revenue $29.0K, net income −$27.6M, EPS −$0.09
- Quarter ended Sep 30, 2024: revenue $0, net income −$82.1M, EPS −$0.31
- Quarter ended Jun 30, 2024: revenue $0, net income −$58.3M, EPS −$0.22
- Quarter ended Mar 31, 2024: revenue $10.1M, net income −$52.7M, EPS −$0.24
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$77.2M, EPS −$0.45
- Quarter ended Sep 30, 2023: revenue n/a, net income −$45.8M, EPS −$0.26
- Quarter ended Jun 30, 2023: revenue n/a, net income −$45.6M, EPS −$0.26
- Quarter ended Mar 31, 2023: revenue n/a, net income −$39.8M, EPS −$0.23
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$27.0M, EPS −$0.23
- Quarter ended Sep 30, 2022: revenue n/a, net income −$42.8M, EPS −$0.47
- Quarter ended Jun 30, 2022: revenue n/a, net income −$42.1M, EPS −$0.46
- Quarter ended Mar 31, 2022: revenue n/a, net income −$37.1M, EPS −$0.41
- Quarter ended Mar 31, 2021: revenue $269K, net income −$33.3M, EPS −$0.53
AUTL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$284M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$206M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$146M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$112M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$118M, share buybacks n/a
AUTL balance sheet
- Jun 30, 2026: cash $171M, total assets $493M, total liabilities $418M, shareholders' equity $74.8M
- Mar 31, 2026: cash $131M, total assets $527M, total liabilities $418M, shareholders' equity $109M
- Dec 31, 2025: cash $104M, total assets $589M, total liabilities $411M, shareholders' equity $178M
- Sep 30, 2025: cash $86.1M, total assets $662M, total liabilities $396M, shareholders' equity $265M
- Jun 30, 2025: cash $124M, total assets $721M, total liabilities $375M, shareholders' equity $346M
- Mar 31, 2025: cash $95.8M, total assets $746M, total liabilities $375M, shareholders' equity $371M
- Dec 31, 2024: cash $227M, total assets $783M, total liabilities $355M, shareholders' equity $427M
- Sep 30, 2024: cash $657M, total assets $827M, total liabilities $351M, shareholders' equity $477M
What is AUTL's revenue?
AUTOLUS THERAPEUTICS LTD reported $117M of revenue over its last four quarters, through June 30, 2026.
Is AUTL profitable?
No. AUTOLUS THERAPEUTICS LTD lost $280M over the last four quarters.
What is AUTL's EPS?
Diluted earnings per share over the last four quarters were −$1.06; −$0.15 in the latest quarter.